



AGENIX LIMITED
7 Durbell Street P.O. Box 391
Acacia Ridge QLD 4110
Australia
Tel : +61 (0)7 3370 6396
Fax : +61 (0)7 3370 6370
Website : www.agenix.com



06013328

82-34639

SEC#82-5258

28 April 2006

US Securities and Exchange Commission
Attention: Filing Desk
450 Fifth Street NW
WASHINGTON DC 20549
USA



SUPL

Dear Sir

Re: Submission Under Rule 12g3-2(b) - Agenix Limited

We refer to the attached announcement that was made to the Australian Stock Exchange on 24 April 2006.

We are providing a copy of the announcement by virtue of our requirements under Rule 12g3-2(b).

Yours sincerely

Tony Finn
Joint Company Secretary

PROCESSED

MAY 12 2006



24 April 2006



AGENIX ANIMAL HEALTH TRANSACTION SETTLES

Agenix confirms that it has settled the animal health transaction announced on 7 April 2006 and today received \$6.7 million in cash. As it previously indicated, Agenix will receive a further \$3.3 million progressively as working capital items are realised and operational transfer milestones are completed.

END

For more information, please contact:

Mr Neil Leggett
CEO and Managing Director
Agenix Limited
Ph: 61 7 3370 6300

Agenix Limited [ASX: AGX, OTC (NASDAQ): AGXLY] is a global health and biotechnology company based in Brisbane, Australia. The Company is focused on developing a pipeline of monoclonal antibody-based products.

Agenix's lead candidate is its high-technology ThromboView[®] blood clot-imaging project, which is currently undergoing human trials. ThromboView[®] uses radiolabelled antibodies to locate blood clots in the body, and could revolutionise the US \$3 billion global clot diagnostic imaging market. ThromboView[®] is being developed with the assistance of the Federal Government through its START scheme.

Agenix employs 90 staff and sells human and animal diagnostic products to more than 50 countries. ThromboView[®] is a registered trademark of AGEN Biomedical Ltd, a wholly owned subsidiary of Agenix Limited.

www.agenix.com